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of suppressive antiretroviral therapy in an African
adult HIV treatment cohort
Lois Bayigga1, Rose Nabatanzi1, Prossy Naluyima Sekiziyivu2, Harriet Mayanja-Kizza3, Moses R Kamya3,
Andrew Kambugu4, Joseph Olobo1, Agnes Kiragga4, Sam Kirimunda1, Moses Joloba1 and Damalie Nakanjako3,4*Abstract
Background: Up to 40% of HIV-infected individuals receiving Highly Active Antiretroviral Therapy (HAART) have
poor CD4+ T-cell recovery. The role of natural killer (NK) cells in immune recovery during HAART is not well
understood. We described the profiles of NK cell subsets and their expression of activating receptor, NKG2D and
cytotoxicity receptor NKp46 among suboptimal immune responders to despite four years of suppressive HAART.
Methods: A case control study utilized frozen peripheral blood mononuclear cells (PBMC) from a cohort of
HIV-infected adults that initiated HAART in 2004/5, at CD4 < 200 cells/μl. Cases were ‘suboptimal’ responders;
patients within the lowest quartile of CD4+ T-cell reconstitution, with a median CD4 count increase of 129 (-43-199)
cells/μl (difference between CD4 count at baseline and after 4 years of HAART) and controls were ‘super-optimal’
responders; patients within the highest quartile of CD4 T-cell reconstitution with a median CD4 count increase of 528
(416-878) cells/μl). Expression of NK cell lineage markers (CD56+/-CD16+/-) and receptors NKG2D and NKp46, was
measured among PBMC from 29 cases of ‘suboptimal’ responders’ and 23 controls of ‘super-optimal responders’, and
compared among ‘suboptimal’ and ‘super-optimal’ responders. NK cell populations were compared using the Holm
Sidak multiple comparison test and p values < 0.05 were considered statistically significant. Data was analyzed using
FLOWJO and GraphPad Prism 6.
Results: ‘Suboptimal responders’ had a higher proportion of cytokine producing CD56++CD16+/- (CD56bri) NK cells than
the ‘super-optimal responders’ p = 0.017, and CD56neg NK cells were lower among suboptimal than super-optimal
responders (p = 0.007). The largest NK cell subset, CD56dim, was comparable among suboptimal responders and
‘super-optimal immune responders’. Expression of NKG2D and NKp46 receptors on NK cell subsets (CD56bri, CD56neg
and CD56dim), was comparable among ‘suboptimal’ and ‘super-optimal’ immune responders.
Conclusions: The pro-inflammatory CD56++CD16– NK cells were higher among ‘suboptimal’ responders relative to
‘super-optimal’ responders, despite four years of suppressive HAART. Alteration of NK cell populations could inhibit host
immune responses to infections among suboptimal responders. We recommend further analysis of NK cell function
among suboptimal immune responders in order to inform targeted interventions to optimize immune recovery among
HAART-treated adults.
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Suboptimal immune recovery occurs in up to 40% of
HIV-infected individuals receiving long-term Highly Ac-
tive Antiretroviral Therapy (HAART) in sub-Saharan
Africa (SSA) [1–3]. The exact mechanisms for subopti-
mal immune recovery are not fully established, although
the phenomenon has been associated with low nadir
CD4 count at HAART initiation, irreversible fibrosis of
the reticulo-endothelial system during advanced HIV
disease, persistent T-cell activation and immune exhaus-
tion, among other factors [2,4,5]. There is limited data
on how HIV-associated dysfunction of the innate im-
mune system influences immune recovery, in particular
Natural Killer (NK) cells that are known to participate
in the initiation and development of adaptive immune
responses. NK cells also participate in host innate re-
sponses to viral and intra-cytoplasmic bacterial infections
[6-8], and may have a role in immune recovery among
HAART-treated HIV-infected adults. HIV-associated NK
cell dysfunction has been reported in association with se-
verity of HIV disease [9] and the impaired immune re-
sponses associated with HIV/AIDS [10,11]. In addition,
increased NK cell activation and degranulation have been
associated with Immune Reconstitution Inflammatory
Syndrome (IRIS) and TB/HIV co-infections [12,13], which
contribute to HIV-associated morbidity and mortality
during HAART [14–16]. There is a need to understand
the role of innate immune dysfunction in post-HAART
immune recovery, to inform therapeutic advances to op-
timize HIV treatment outcomes. This paper explores the
association of NK cells with immune recovery during sup-
pressive HAART in an African HIV treatment cohort.
The role of the innate immune system in HIV immune-
pathogenesis has been explored with particular focus on
NK cell subsets, function and expression of receptors
[11,17–19]. Three distinct subsets of NK cells are recog-
nized in human peripheral blood; CD56bri, CD56dim and
CD56neg; categorized according to the expression of NK
cell lineage markers CD56 and CD16 [20,21]. CD56bri are
pre-dominantly cytokine producing cells and CD56dim are
mainly cytotoxic [22]. NK cell function is directed by a
complex repertoire of activating and inhibitory natural
cytotoxicity receptors (NCRs), such as NKp46, NKp30
and NKp44, as well as NKG2D, CD16, 2B4 and NKp80
[22]. During HIV infection, NK cells are directly infected
[23] and the distribution of NK cell subsets is altered [20];
with an expansion of CD56neg among viremic patients
[20]. In addition, HIV causes up-regulation of inhibitory
natural killer receptors (iNKRs) leading to impairment of
NK cell lysis of virally-infected cells [11]. Antiretroviral
therapy reverses the effects of HIV infection on NK cells;
however, there is no consensus on the degree to which
suppression of HIV replication restores NK cell function
[10]. We hypothesized that the distribution and functionof NK cell subsets differs among individuals with poor ver-
sus excellent CD4+ T-cell recovery during antiretroviral
therapy. This study describes the profiles of NK cell sub-
sets and their expression of activating receptors, NKG2D
and cytotoxicity receptor NKp46, among individuals with
poor CD4 T-cell reconstitution relative to individuals with
excellent CD4 T-cell count reconstitution after four years
of suppressive HAART. Our results highlight the need for
studies to further understand the short and long-term
recovery of the innate immune system including NK
cell function among African HAART-treated HIV-infected
patients.
Methods
Study design and participants
Using a case-control study design, NK cell populations
and their receptors were evaluated among ‘suboptimal’
immune responders (cases) and ‘super-optimal’ immune
responders (controls) after four years of HAART within
the Infectious Diseases Institute (IDI) research cohort.
This study utilized frozen peripheral blood mononuclear
cells (PBMC) that were collected from a Ugandan Adult
HIV Treatment Cohort that was previously described
[4]. Between April, 2004 and April, 2005, 559 HAART-
naïve HIV-infected adults were consecutively initiated
on HAART, and enrolled in a prospective observational
research cohort. HIV RNA viral load and CD4 count
measurements were done every six months and viral
suppression was considered at <400 copies/ml. After
four years of HAART, individuals that were still in care,
with sustained viral suppression and no history of op-
portunistic infections in the six months preceding the
study, were included in the study. Individual CD4 count
increases (difference between CD4 count at HAART ini-
tiation and CD4 count after 4 years of HAART) of study
participants were grouped into quartiles. ‘Suboptimal’ re-
sponders were patients within the lowest quartile of
CD4+ T-cell reconstitution with a median CD4 count
increase (minimum-maximum) of 129 (43–199) cells/μl
and ‘super-optimal’ responders were patients within the
highest quartile of CD4 T-cell reconstitution with a me-
dian CD4 count increase of 528 (416–878) cells/μl); see
Figure 1. All participants in the parent study provided
written informed consent for storage of biological sam-
ples for further immunological studies. This study was
approved by the School of Biomedical Sciences Institu-
tional review board with final approval by the Uganda
National Council for Science and Technology. Labora-
tory assays were conducted at the Immunology labo-
ratory Department of Microbiology, College of Health
Sciences and the IDI translational laboratory that is
within the same complex. Flow cytometry assays were
conducted using an eight-colour FACS Canto II (BD
Biosciences) Flow cytometer.
252 had sustained viral suppression up to 4 years
25 died
16 transfer/lost to follow-up
211 eligible for the study
Sub-optimal responders
Lowest quartile (n=52)
Median CD4 increase = 129
cells/µl
(Range= -43-199) cells/µl
29 samples were conveniently
selected for NK assays
Super-optimal responders
Highest quartile (n=52)
Median CD4 increase= 528 cells/µl
(Range=416-878) cells/µl
23 samples were conveniently 
selected for NK assays
Optimal responders
2nd and 3rd quartiles (n=104)
Median CD4 increase=282 cells/µl
(Range=200-415) cells/µl
Cohort profile of immune recovery after 4 years of HAART
Figure 1 Profile of patients on antiretroviral therapy in the Infectious Diseases research cohort. Natural Killer (NK) cell populations and
expression of activating receptors were compared among ‘suboptimal’ immune responders (cases) and ‘super-optimal’ immune responders (controls).
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This study utilized frozen PBMC that were previously
collected using the Ficoll-Paque method and stored in li-
quid nitrogen [24]. PBMC were thawed in a water-bath
at 37°C for one minute and thereafter, washed and re-
suspended in RPMI media containing 10% v/v fetal calf
serum before surface staining. PBMC viability was evalu-
ated using trypan blue dye and viable cells were counted
under microscopy. Minimum cell viability was 80%. Cells
were rested for four hours, and subsequently stained with
the following anti-human monoclonal antibodies; CD14/
19 FITC CD3 Amcyan, CD8 APC-Cy7, CD16 PerCP
Cy5.5, CD56 PE Cy7, NKG2D PE and NKp46 APC (BD
Biosciences, San Jose CA). At least 50,000 events in the
CD3-negative gate were collected. Gating was standard-
ized and set using fluorescence minus one control (FMOs)
for CD14/19, CD16, CD56, NKG2D and NKp46. NK
cells were identified as CD3-negative, CD14-/CD19- and
NK cell subsets were identified by co-expression of
CD56 and CD16 on NK cells; CD56bri (CD56++CD16-),
CD56INTERMEDIATE (CD56+CD16-), CD56dim (CD56+CD16+)
and CD56neg (CD56-CD16+); see Figure 2. Expression of NK
receptors NKG2D and NKp46 was defined by the percent-
age of NKG2D+ and NKp46+ NK cell subsets (Figure 3).
Statistical analysis
Data obtained from flow cytometry was analyzed using
FLOWJO version 7.6.3 software (TreeStar, San Carlos,CA), exported to Excel spreadsheets and subsequently ana-
lyzed using GraphPad Prism 6. NK cell populations and ex-
pression of NK surface receptors NKG2D and NKp46 were
compared among ‘suboptimal’ and ‘super-optimal’ immune
responders, using the Holm Sidak multiple comparison test
and p values < 0.05 were considered statistically significant.
Results
NK cell subsets in peripheral blood after four years of
suppressive HAART
Overall, the largest NK cell subset was the CD56dim;
accounting for an average of 59% of NK cells among sub-
optimal responders and 57% of NK cells among ‘super-
optimal responders’. The proportions of CD56bri were the
lowest among both sub-optimal and optimal responders
(Figure 4). CD56bri (cytokine producing) NK cells were
higher in suboptimal than super-optimal responders, p =
0.017, and CD56neg NK cells were lower among subopti-
mal than super-optimal responders (p = 0.007).
Expression of NKG2D and NKp46 receptors on NK cells
among ‘sub-optimal’ and ‘super-optimal’ responders
Expression of NKG2D receptor was comparable among
suboptimal and super-optimal responders; CD56bri (CD
56++CD16-NKG2D+), p = 0.376; CD56neg (CD56-CD16+NK
G2D+), p = .0.221 and CD56dim (CD56+CD16+/-NKG2D+),
p = 0.428 (Figure 5). Similarly, NKp46 expression was com-
parable among suboptimal and super-optimal responders;
Figure 2 Gating strategy for NK cells. A- Total lymphocyte population, B- CD3 negative CD8 variable NK cells gated from the total lymphocyte
population, C- CD14-/19- cells, D- total NK cell population gated off the CD14-/19- cells, E- different NK cell subsets; CD56bri (cytokine-producing
NK cells)-CD56++ CD16-, CD56 dim (cytotoxic NK cells) -CD56+CD16+/-, CD56 neg (cytotoxic NK cells)-CD56-CD16+, F- CD16 PerCP-cy5.5 FMO,
G- CD56 PE-Cy7 FMO and H- CD14/19-FITC FMO.
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56-CD16+NKp46+), p = 0.185 and CD56dim (CD56+CD
16+/-NKp46+); p = 0.282 (Figure 5).
Discussion
This study compared proportions of NK cell subsets as
well as expression of activating receptor NKG2D andcytotoxicity receptor NKp46 among adults with ‘subopti-
mal’ and ‘super-optimal’ immune recovery despite four
years of suppressive HAART. We found that CD56dim
was the largest NK cell subset among HAART-treated
adults, irrespective of immune recovery status. Our data
is consistent with previous reports that CD56dim is the
largest population of NK cells in peripheral blood and
Figure 3 Gating strategy for expression of NKp46 and NKG2D by CD56+ dim NK cells: Panel A shows NKp46 APC FMO, B shows CD56dim
expressing NKG2D (CD56+CD16+/- NKG2D+); C shows NKG2D PE FMO and D shows CD56 dim expressing NKG2D (CD56+CD16+/- NKG2D+).
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dependent cell-mediated cytotoxicity (ADCC); followed
by CD56neg and CD56bri NK cells. Whereas the func-
tionally defective CD56-CD16+ (CD56neg) population of
NK cells expands in viremic versus aviremic patients
[11] and is associated with poor cytotoxic function [20],
this subset of NK cells was lower among suboptimal
responders relative to super-optimal responders. Giventhat our study participants had received suppressive
HAART for four years, our data suggests that HIV-
associated expansion of the dysfunctional CD56neg popula-
tion was no longer significant. These results mirror previ-
ous reports that initiating HAART during acute HIV
infection prevented further decline in NK cell subsets and
improved NK cell function [25]. It is therefore likely that
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Figure 4 Comparison of NK cell subsets among suboptimal and
super-optimal immune responders after four years of suppressive
antiretroviral therapy. Figure 4 shows comparison of mean
percentages of NK cell subsets (CD56bri, CD56neg and CD56dim)
among sub-optimal and super-optimal responders using the Holm
Sidak multiple comparison test.
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WHO guidelines [26], may result into faster recovery of
HIV-associated NK cell dysfunction; among other benefits.
The CD56++CD16- (CD56bri) subset, functionally cy-
tokine producers, was higher among ‘suboptimal’ re-
sponders relative to ‘super-optimal’ responders. The high
numbers of cytokine producing NK cells among ‘sub-
optimal’ responders may be reflective of the persistently
high levels of immune activation that were previously
documented among suboptimal responders in our co-
hort [4]. Immune activation has been associated with
high production of inflammatory cytokines and in-
creased turn-over of T-cells, B lymphocytes, NK cells
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Figure 5 Expression of NK activating receptors NKG2D and NKp46 on
after four years of suppressive antiretroviral therapy. A shows NKG2Dfirst few years of HAART-mediated viral suppression
predicted long-term CD4+ T-cell recovery after 15 years
of antiretroviral therapy. It is likely that pre-HAART im-
mune activation, not only predicts mortality during
HAART [29], but also predicts suboptimal immune
recovery including suboptimal reversal of the HIV-
associated NK cell dysfunction. We therefore postulate
that controlling immune activation among HIV-infected
individuals may also stabilize the NK cytokine producing
cells, modulate their immune function and subsequently
optimize short and long-term immune recovery during
antiretroviral therapy.
Expression of NKG2D and NKp46 receptors by NK cells
was comparable among suboptimal and super-optimal
responders. NK activating receptors correlate with the
NK effector function [30,31], so it is likely that NK effector
function is comparable among suboptimal and super-
optimal responders. We could attribute this result to
suppressive HAART that has provided partial immune
recovery during the first four years. It has been previ-
ously shown that HAART modulates NKG2D receptor
expression among HIV-infected viremic individuals
[10,13,21]. Increased NKp46 expression on NK cells
was previously shown to correlate with HIV-1 disease
severity among HIV-infected children [9], although its
role in immune recovery is not yet well understood.
Although we did not perform NK functional assays, pre-
vious data shows that abnormal expression of NK acti-
vating and inhibitory receptors was associated with
impaired cytolytic function [11]. In addition, reduced
surface expression of the NK cytotoxicity receptor,
NKp46 was associated with poor cytolytic function dur-
ing viremic HIV disease [21]. Given that NKG2D and
NKp46 expression was similar in the ‘suboptimal’ and
‘super-optimal’ immune responders, it is likely that
these receptors are not involved in the mechanisms that
lead to poor CD4+ T-cell reconstitution in HIV-
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B
NK subsets among suboptimal and super-optimal responders
expression and B shows NKp46 expression.
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activation is controlled by a dynamic balance between
complementary and antagonistic pathways [31,32]. We did
not evaluate NK cell surface inhibitory receptors that
antagonize activating pathways through protein tyrosine
phosphatases (PTPs), therefore our data is not conclusive
on the NK cell activation status in the study population.Implications of the study
Our results imply that after four years of suppressive
antiretroviral therapy, the HIV-associated NK cell dys-
function was only partially restored, with a predominant
CD56dim (CD56 + CD16-/+) population and a high
CD56bri (CD56++CD16-) NK cell population among sub-
optimal responders. The high CD56bri, functionally cyto-
kine producers, among suboptimal responders may be
reflective of the persistently high levels of immune acti-
vation previously described in the same cohort [4]. We
postulate that earlier initiation of HAART and control of
immune activation could contribute to faster and more
comprehensive recovery of the immune system. It is also
important to note the trend shown that specific T-cell
subsets recover faster, while other subsets require longer
periods of suppressive HAART. Given the significant
cytokine producing function of CD56bri NK cells, it
might be worthwhile to further investigate NK cell dys-
function among individuals that initiate HAART at CD4
< 500 cells before severe damage of the immune system,
as well as potential interventions to enhance compre-
hensive immune recovery. In addition, increased NK cell
degranulation capacity was significantly associated with
Immune Reconstitution Inflammatory Syndrome (IRIS)
among HIV/TB co-infected individuals in Cambodia,
with activating receptor expression higher among IRIS
patients relative to non-IRIS patients [17]. Similarly NK
cell activation was shown to distinguish Mycobacterium
tuberculosis-mediated IRIS from chronic HIV and HIV/
TB co-infection [12]. Thus, further examination of the
mechanisms of NK cell dysfunction, co-infections and
suboptimal recovery is critical for suboptimal immune
responders that remain at risk of life-threatening oppor-
tunistic infections [1,24].Limitations
We did not perform NK cell function assays due to
logistical limitations. In addition, this study was limited
to the extremes of immune recovery (suboptimal and
super-optimal immune responders), and did not include
average responders. Our results, however, highlight the
need for NK function assays to conclusively ascertain
defects in NK cell effector function that might be rele-
vant to immune responses to viral and bacterial infec-
tions among HAART-treated HIV-infected adults.Conclusion
The pro-inflammatory CD56++CD16- NK cells were higher
among ‘suboptimal’ responders relative to ‘super-optimal’
responders, despite four years of suppressive HAART.
Alteration of NK cell populations could inhibit host
immune responses to infections among suboptimal re-
sponders. We recommend further analysis of NK cell
function among suboptimal immune responders to in-
form targeted interventions to optimize immune recov-
ery among HAART-treated adults.
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